Skip to main content

Table 3 Outcomes of the subgroup analysis

From: Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis

 

No. of studies

Heterogeneity test

Effect size

I2 (%)

PH

WMD/RR (95% CI)

P

Platelet reactivity (PRU)

 Type of studies

  RCT

5

86

< 0.001

−29.93 (−70.21, 10.36)

0.15

  Cohort

2

87

0.005

−37.55 (−65.66, −9.44)

0.009

 Testing time

   < 24 h after the loading dose

3

87

0.005

−22.48 (−105.72, 60.76)

0.60

  5–30 days after initiation of treatment

4

76

0.006

−36.72 (−57.04, −16.40)

< 0.001

 Special Population

  STEMI

3

67

0.05

−5.77 (−34.85, −23.31)

0.70

  Diabetic patients

1

–

–

− 10.90 (−43.61, 21.81)

0.514

Platelet reactivity (PRI)

 Type of studies

  RCT

5

88

< 0.001

−10.51 (− 16.17, −4.85)

< 0.001

  Cohort

2

0

0.319

−5.36 (−9.97, −0.76)

0.023

 Testing time

   < 24 h after the loading dose

3

89

< 0.001

−10.30 (−19.70, −0.90)

0.032

  5–30 days after initiation of treatment

4

81

< 0.001

−8.91 (−15.03, −2.79)

0.004

 Special Population

  STEMI

2

0

0.650

−3.69 (−7.63, 0.26)

0.067

  Diabetic patients

1

–

–

−10.40 (−17.96, −2.84)

0.007

HTPR rates (PRU) a

 Type of studies

  RCT

1

–

–

5.00 (0.25, 99.51)

0.29

  Cohort

1

–

–

0.03 (0.00, 0.52)

0.016

 Testing time

  5–30 days after initiation of treatment

2

84

0.01

0.39 (0.001, 62.72)

0.71

HTPR rates (PRI)

 Type of studies

  RCT

5

20

0.290

0.30 (0.12, 0.75)

0.010

 Testing time

   < 24 h after the loading dose

2

0

0.440

0.31 (0.10, 0.98)

0.047

  5–30 days after initiation of treatment

3

69

0.073

0.24 (0.03, 2.08)

0.197

 Special Population

  STEMI

1

–

–

0.11 (0.01, 2.00)

0.137

  Diabetic patients

1

–

–

0.38 (0.11, 1.33)

0.129

LTPR rates (PRI)

 Type of studies

  RCT

4

82

0.0008

1.63 (0.95, 2.80)

0.073

  Cohort

2

85

0.009

1.31 (0.98, 1.76)

0.066

 Testing time

   < 24 h after the loading dose

2

0

0.898

1.09 (0.86, 1.39)

0.462

  5–30 days after initiation of treatment

4

89

< 0.001

1.69 (1.12, 2.56)

0.012

 Special Population

  STEMI

2

0

0.634

1.15 (1.01, 1.30)

0.029

  Diabetic patients

1

–

–

1.11 (0.79, 1.56)

0.545

  1. a three studies don’t involved in the results of STEMI or Diabetic patients
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us